FDA Clears Medtronic's InPen App for Smart MDI System with Simplera CGM
核心洞察
Medtronic receives FDA clearance for its updated InPen (搜索) app, designed for use with the Simplera CGM (搜索) system, enhancing its smart multiple daily injection (MDI) system.
The InPen (搜索) system is the first smart MDI system capable of recommending corrections for missed or inaccurate insulin doses, offering personalized insights.
This integration aims to reduce the complexities of diabetes (搜索) management for MDI users by providing real-time support for insulin dosing decisions.
Medtronic has secured FDA clearance for its new InPen (搜索) insulin delivery system application, paving the way for the launch of its smart multiple daily injection (MDI) system. This system integrates with the recently FDA-cleared, next-generation Simplera continuous glucose monitor (CGM).
The InPen (搜索) system stands out as the first on the market to recommend corrections for missed or inaccurate insulin doses. It aims to provide real-time, personalized insights for individuals on MDI therapy, addressing the challenges they face in daily insulin dosing decisions. Medtronic emphasizes that this smart MDI system is designed to reduce the guesswork involved in diabetes (搜索) management, meeting a critical unmet need for MDI users.